Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRX518 Monotherapy and Combination in Advanced Solid Tumors
NCT02628574Phase 1Completed
- Sponsor
- Leap Therapeutics, Inc.
- Start
- Jan 2016
- Primary completion
- Jul 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of trx518 in solid tumor (4 arms), sponsored by Leap Therapeutics, Inc. Primary endpoint: Adverse events. Started Jan 2016; status: completed.
02
Drugs
trx518
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02628574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02628574.